Recommendation of the President – Disulone (dapsoneum)

On 18 October 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 100/2024 on the evaluation of the medicinal product Disulone (dapsoneum) for the indications: Duhring’s disease, Sneddon Wilkinson disease, pemphigoid, linear IgA bullous dermatosis, IgA-related vasculitis, Hailey-Hailey disease, pemphigus, pyoderma gangrenosum, nodular vasculitis, urticaria vasculitis, allergic vasculitis, leukocytoclastic vasculitis, erythema nodosum, systemic lupus erythematosus, capillaritis chronic, granuloma annulare, ulcers of the lower extremity (not elsewhere classified)

Publication in Public Information Bulletin (BIP) >>